Published April 28, 2026 | Version v1
Preprint Open

Fenofibrate Repurposing for Metabolic Cardiomyopathy

Authors/Creators

  • 1. MedicOath

Description

OpenFDA shows fenofibrate approved as PPAR-alpha agonist for lipid disorders. PPAR-alpha activation improves cardiac fatty acid oxidation and energy metabolism. This could treat metabolic cardiomyopathy in diabetes and obesity by restoring normal cardiac fuel utilization and reducing lipotoxicity.

Notes

IPFS: QmVxzKCrJMNmBXZ1saeYKeH2qH4odNAa7EihMTi789wzbH. TX: 0x54dbd84fce43fee920b08b9146957f9f7ef352d95d6c874096f94e1bfbb24243. CC0.

Files

hypothesis.json

Files (323 Bytes)

Name Size
md5:1320e2ce3dab364fc6d2fd7856ecc730
323 Bytes Preview Download